Xeris制药（股票代码：XERS）今日盘中大涨6.14%，引发投资者关注。这一显著涨幅主要源于公司发布的最新季度财报超出市场预期。
根据公司公布的财报显示，截至3月31日的季度，Xeris制药实现营收6012万美元，同比增长47.9%，超过分析师预期的5761万美元。尽管公司仍处于亏损状态，但本季度调整后每股亏损6美分，相比去年同期的每股亏损14美分有明显改善。值得注意的是，虽然亏损略高于分析师平均预期的每股亏损5美分，但仍在华尔街预期的每股亏损8美分至1美分区间内。
此外，分析师对Xeris制药的前景保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中5个评级为"强烈买入"或"买入"，1个为"持有"，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为6.25美元。这种积极的市场情绪，加上公司业绩的改善，共同推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.